- Home
- TBPH vs BUI Comparison
TBPH vs BUI Comparison
Compare TBPH & BUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- BUI
- Stock Information
- Founded
- TBPH 2013
- BUI 2011
- Country
- TBPH United States
- BUI United States
- Employees
- TBPH N/A
- BUI N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- BUI Trusts Except Educational Religious and Charitable
- Sector
- TBPH Health Care
- BUI Finance
- Exchange
- TBPH Nasdaq
- BUI Nasdaq
- Market Cap
- TBPH 699.0M
- BUI 589.4M
- IPO Year
- TBPH N/A
- BUI N/A
- Fundamental
- Price
- TBPH $18.81
- BUI $25.78
- Analyst Decision
- TBPH Strong Buy
- BUI
- Analyst Count
- TBPH 4
- BUI 0
- Target Price
- TBPH $24.25
- BUI N/A
- AVG Volume (30 Days)
- TBPH 569.5K
- BUI 59.8K
- Earning Date
- TBPH 11-10-2025
- BUI 01-01-0001
- Dividend Yield
- TBPH N/A
- BUI 6.79%
- EPS Growth
- TBPH N/A
- BUI N/A
- EPS
- TBPH 0.58
- BUI 2.75
- Revenue
- TBPH $80,327,000.00
- BUI N/A
- Revenue This Year
- TBPH $79.82
- BUI N/A
- Revenue Next Year
- TBPH N/A
- BUI N/A
- P/E Ratio
- TBPH $32.54
- BUI $7.77
- Revenue Growth
- TBPH 27.12
- BUI N/A
- 52 Week Low
- TBPH $7.90
- BUI $18.73
- 52 Week High
- TBPH $18.96
- BUI $24.22
- Technical
- Relative Strength Index (RSI)
- TBPH 68.84
- BUI 41.59
- Support Level
- TBPH $17.50
- BUI $25.53
- Resistance Level
- TBPH $18.58
- BUI $26.67
- Average True Range (ATR)
- TBPH 0.99
- BUI 0.38
- MACD
- TBPH 0.16
- BUI -0.05
- Stochastic Oscillator
- TBPH 98.49
- BUI 19.69
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About BUI BlackRock Utility Infrastructure & Power Opportunities Trust
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.